Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein InhibitorXiufang Zheng, Hongying Yun, Song Feng et al.|Journal of Medicinal Chemistry|2019Cited by 96
Role of the PI3K‑AKT‑mTOR pathway in hepatitis B virus infection and replicationKunlun Xiang, Bin Wang|Molecular Medicine Reports|2018Cited by 49